BR112013033488A2 - marcadores biológicos de micro-rna indicativo da doença de alzheimer - Google Patents

marcadores biológicos de micro-rna indicativo da doença de alzheimer

Info

Publication number
BR112013033488A2
BR112013033488A2 BR112013033488A BR112013033488A BR112013033488A2 BR 112013033488 A2 BR112013033488 A2 BR 112013033488A2 BR 112013033488 A BR112013033488 A BR 112013033488A BR 112013033488 A BR112013033488 A BR 112013033488A BR 112013033488 A2 BR112013033488 A2 BR 112013033488A2
Authority
BR
Brazil
Prior art keywords
disease
alzheimer
subject
micro
mirna
Prior art date
Application number
BR112013033488A
Other languages
English (en)
Other versions
BR112013033488B1 (pt
BR112013033488B8 (pt
Inventor
Kumar Pavan
Dezso Zoltan
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112013033488A2 publication Critical patent/BR112013033488A2/pt
Publication of BR112013033488B1 publication Critical patent/BR112013033488B1/pt
Publication of BR112013033488B8 publication Critical patent/BR112013033488B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

abstract the invention provides a method of diagnosing alzheimer's disease in a subject, by determining the level of at least one mirna in a sample derived from the subject, wherein a change in the level of the at least one mirna relative to a suitable control is indicative of alzheimer's disease in the subject. methods for monitoring the course of alzheimer's disease, methods of treating a subject having alzheimer's disease, and kits for diagnosing alzheimer's disease are also provided. ******************************************************** tradução do resumo resumo patente de invenção: "marcadores biológicos de micro-rna indicativo da doença de alzheimer". a presente invenção refere-se a um método para diagnosticar doença de alzheimer em um sujeito, pela determinação do nível de pelo menos um mirna em uma amostra derivada do sujeito, em que uma alteração no nível do pelo menos um mirna em relação a um controle adequado é indicativo da doença de alzheimer no sujeito. métodos para monitoramento do curso da doença de alzheimer, métodos de tratamento de um sujeito tendo doença de alzheimer, e kits para diagnosticar doença de alzheimer são providos também.
BR112013033488A 2011-06-27 2012-06-26 Métodos para facilitar o diagnóstico do comprometimento cognitivo devido a doença de alzheimer ou comprometimento cognitivo leve (mci)e kit BR112013033488B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501720P 2011-06-27 2011-06-27
US61/501,720 2011-06-27
PCT/US2012/044202 WO2013003350A2 (en) 2011-06-27 2012-06-26 Microrna biomarkers indicative of alzheimer's disease

Publications (3)

Publication Number Publication Date
BR112013033488A2 true BR112013033488A2 (pt) 2017-03-01
BR112013033488B1 BR112013033488B1 (pt) 2022-03-03
BR112013033488B8 BR112013033488B8 (pt) 2022-11-22

Family

ID=46724591

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033488A BR112013033488B8 (pt) 2011-06-27 2012-06-26 Métodos para facilitar o diagnóstico do comprometimento cognitivo devido a doença de alzheimer ou comprometimento cognitivo leve (mci)e kit

Country Status (13)

Country Link
US (1) US9771617B2 (pt)
EP (1) EP2723894B1 (pt)
JP (2) JP6154809B2 (pt)
KR (1) KR102082016B1 (pt)
CN (1) CN103781919B9 (pt)
AU (1) AU2012275556B2 (pt)
BR (1) BR112013033488B8 (pt)
CA (1) CA2840196C (pt)
ES (1) ES2580379T3 (pt)
IL (1) IL230034B (pt)
MX (1) MX341840B (pt)
RU (1) RU2639509C2 (pt)
WO (1) WO2013003350A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838562A1 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
WO2015050835A1 (en) * 2013-10-01 2015-04-09 Advanced Genomic Technology, Llc Circulating biomarkers for alzheimer's disease and/or mild cognitive impairment
WO2015134551A1 (en) * 2014-03-03 2015-09-11 Banyan Biomarkers, Inc. Micro rna markers for diagnosis of a neurological condition
KR101583450B1 (ko) * 2014-12-01 2016-01-11 전주대학교 산학협력단 마이크로 rna id의 분석방법 및 이를 통해 도출한 대장암의 바이오마커
WO2016148073A1 (ja) 2015-03-13 2016-09-22 国立大学法人広島大学 アルツハイマー病又は軽度認知症の検出を補助する方法
US10358676B2 (en) * 2015-04-03 2019-07-23 Kaohsiung Chang Gung Memorial Hospital Methods and kits for detecting Kawasaki disease
KR101734645B1 (ko) * 2015-05-18 2017-05-11 (주)에이엔티랩스 초기 알츠하이머 병 또는 경도 인지 장애 진단 방법
CN108027376B (zh) 2015-09-16 2021-04-02 株式会社岛津制作所 评价脑内的淀粉样蛋白β蓄积状态的多重生物标记物及其分析方法
ES2734678T3 (es) * 2015-12-22 2019-12-11 Siemens Ag Firmas específicas en enfermedad de alzheimer por perfiles de miarn multicéntricos
US10262423B2 (en) * 2016-03-29 2019-04-16 Verily Life Sciences Llc Disease and fall risk assessment using depth mapping systems
WO2017186719A1 (en) * 2016-04-25 2017-11-02 Instytut Biologii Doswiadczalnej Im. Marcelego Nenckiego Polska Akademia Nauk Microrna biomarkers in blood for diagnosis of alzheimer's disease
KR101998457B1 (ko) * 2016-05-10 2019-07-10 조선대학교산학협력단 알츠하이머 질병의 진단을 위한 바이오마커
KR101992539B1 (ko) * 2016-10-21 2019-09-30 서울대학교산학협력단 miRNA 기반의 인지장애 질환 진단용 조성물 및 방법
WO2018228875A1 (en) * 2017-06-15 2018-12-20 Nestec S.A. Micro-rna biomarkers of blood-brain barrier dysfunction
EP4289970A3 (en) * 2017-06-19 2024-03-13 St. John's University Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis
CA3069445A1 (en) 2017-07-12 2019-01-17 P. Hemachandra REDDY Microrna-455-3p as a peripheral biomarker for alzheimer's disease
US11078535B2 (en) 2017-07-18 2021-08-03 The Trustees Of Indiana University Presymptomatic micro RNA targets for treatment of neurodegeneration pathology
CN111344409A (zh) * 2017-11-12 2020-06-26 加利福尼亚大学董事会 用于检测癌症的非编码rna
WO2019117306A1 (ja) 2017-12-14 2019-06-20 国立大学法人広島大学 アルツハイマー病の検出を補助する方法
CN108277271A (zh) * 2018-02-05 2018-07-13 范瑶飞 一种辅助检测阿兹海默疾病的miRNA
JP7414237B2 (ja) * 2018-02-13 2024-01-16 東レ株式会社 認知症の検出のためのキット又はデバイス及び方法
US20210262030A1 (en) 2018-06-15 2021-08-26 Universitat Autonoma De Barcelona Circulating mirnas as biomarkers for diagnosis of mild cognitive impairment and alzheimers disease
KR20210038585A (ko) * 2018-07-25 2021-04-07 에스알엔에이리틱스, 인크. 알츠하이머병에 대한 작은 rna 예측인자
JP6884810B2 (ja) * 2019-05-08 2021-06-09 キユーピー株式会社 情報提供装置、情報提供方法及びｍｉＲＮＡ重要度テーブル生成方法
WO2022019786A1 (en) * 2020-07-24 2022-01-27 Otago Innovation Limited Biomarkers for cognitive conditions
WO2022165205A1 (en) * 2021-01-29 2022-08-04 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods for diagnosing neurodegenerative diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5965364A (en) 1990-10-09 1999-10-12 Benner; Steven Albert Method for selecting functional deoxyribonucleotide derivatives
US5767259A (en) 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
JP3898228B2 (ja) 1996-04-12 2007-03-28 ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク 検出プローブ、キット及びアッセイ
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
ATE478090T1 (de) 1997-10-27 2010-09-15 Boston Probes Inc SICH AUF ßPNA MOLECULAR BEACONSß BEZIEHENDE VERFAHREN, TESTSÄTZE UND ZUSAMMENSETZUNGEN
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6383752B1 (en) 1999-03-31 2002-05-07 Hybridon, Inc. Pseudo-cyclic oligonucleobases
AU779635B2 (en) 1999-10-27 2005-02-03 Health Discovery Corporation Methods and devices for identifying patterns in biological systems and methods for uses thereof
US6528254B1 (en) 1999-10-29 2003-03-04 Stratagene Methods for detection of a target nucleic acid sequence
US6596490B2 (en) 2000-07-14 2003-07-22 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
NZ524171A (en) 2000-07-18 2006-09-29 Correlogic Systems Inc A process for discriminating between biological states based on hidden patterns from biological data
US6350580B1 (en) 2000-10-11 2002-02-26 Stratagene Methods for detection of a target nucleic acid using a probe comprising secondary structure
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US7060809B2 (en) 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
US6593091B2 (en) 2001-09-24 2003-07-15 Beckman Coulter, Inc. Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
JP2004161636A (ja) 2002-11-11 2004-06-10 Takeda Chem Ind Ltd 軽度認知障害または注意欠陥多動性障害治療剤
AU2004235349B2 (en) 2003-04-25 2009-11-19 Becton, Dickinson And Company Detection of herpes simplex virus types 1 and 2 by nucleic acid amplification
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
AU2005271961B8 (en) 2004-07-09 2011-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of markers in esophageal cancer, colon cancer, head and neck cancer and melanoma
US20060078894A1 (en) 2004-10-12 2006-04-13 Winkler Matthew M Methods and compositions for analyzing nucleic acids
JP2006176503A (ja) 2004-11-26 2006-07-06 Tohoku Univ 脳血管障害を伴うアルツハイマー病治療薬
RU2418068C2 (ru) * 2005-08-17 2011-05-10 Сирна Терапьютикс, Инк. Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
WO2007044937A2 (en) 2005-10-13 2007-04-19 President And Fellows Of Harvard College Compositions and methods to modulate memory
MX2009001937A (es) * 2006-08-21 2009-04-30 Novartis Ag Biomarcadores para el progreso de la enfermedad de alzheimer.
WO2008153692A2 (en) * 2007-05-22 2008-12-18 The Brigham And Women's Hospital, Inc. Microrna expression profiling of cerebrospinal fluid
CA2687336C (en) * 2007-05-23 2014-12-23 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2009009457A1 (en) * 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Alzheimer's disease-specific micro-rna microarray and related methods
US8551703B2 (en) 2007-07-06 2013-10-08 The Regents Of The University Of California SNPs associated with fatty acid composition of bovine meat and milk
AU2008279016B2 (en) * 2007-07-25 2013-08-22 University Of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
WO2009025852A2 (en) * 2007-08-22 2009-02-26 Xenomics, Inc. Methods of using mirna for detection of in vivo cell death
AU2008298744B8 (en) 2007-09-14 2015-01-15 The Ohio State University Research Foundation MiRNA expression in human peripheral blood microvesicles and uses thereof
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US20110160290A1 (en) 2008-05-21 2011-06-30 Muneesh Tewari Use of extracellular rna to measure disease
CN101386848A (zh) * 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
EP3181705A1 (en) 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2287336A1 (fr) 2009-07-31 2011-02-23 Exhonit Therapeutics SA Procédés et méthodes de diagnostic de la maladie d'Alzheimer
WO2011029903A1 (en) 2009-09-10 2011-03-17 Flemming Velin Method for the preparation of micro-rna and its therapeutic application
US8648017B2 (en) 2009-11-04 2014-02-11 Diamir, Llc Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
GB201011420D0 (en) 2010-07-06 2010-08-18 United Arab Emirates Universit Method for diagnosis
AU2011306941B2 (en) 2010-09-22 2014-06-12 Janssen Pharmaceutica Nv 4,7-dihydro-pyrazolo[1,5-a] pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
KR20140024270A (ko) 2010-12-30 2014-02-28 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
US8945829B2 (en) 2011-03-22 2015-02-03 Cornell University Distinguishing benign and malignant indeterminate thyroid lesions
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment

Also Published As

Publication number Publication date
KR20140044375A (ko) 2014-04-14
CA2840196C (en) 2022-09-20
AU2012275556B2 (en) 2016-02-04
WO2013003350A2 (en) 2013-01-03
CN103781919B9 (zh) 2017-09-15
KR102082016B1 (ko) 2020-02-26
RU2014102357A (ru) 2015-08-10
AU2012275556A1 (en) 2013-05-02
MX341840B (es) 2016-09-05
BR112013033488B1 (pt) 2022-03-03
JP6154809B2 (ja) 2017-06-28
EP2723894B1 (en) 2016-05-11
WO2013003350A3 (en) 2013-04-11
MX2013015392A (es) 2014-07-14
RU2639509C2 (ru) 2017-12-21
IL230034B (en) 2021-02-28
US20140378439A1 (en) 2014-12-25
ES2580379T3 (es) 2016-08-23
BR112013033488B8 (pt) 2022-11-22
CA2840196A1 (en) 2013-01-03
JP2016214256A (ja) 2016-12-22
CN103781919B (zh) 2017-07-04
CN103781919A (zh) 2014-05-07
JP2014520529A (ja) 2014-08-25
EP2723894A2 (en) 2014-04-30
US9771617B2 (en) 2017-09-26

Similar Documents

Publication Publication Date Title
BR112013033488A2 (pt) marcadores biológicos de micro-rna indicativo da doença de alzheimer
BR112014016313A2 (pt) medições precisas de analito para tira de teste eletroquímico com base em característica(s) física(s) detectada(s) da amostra contendo o analito e parâmetros de biossensores derivados
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
EA201590027A1 (ru) Способы детекции заболеваний или состояний
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
BR112013022480A2 (pt) processo para determinação de propriedade de combustível
ES2530843T3 (es) Métodos basados en microARN para el diagnóstico de cáncer de páncreas
BR112015024354A2 (pt) método de determinação do sexo de um embrião em um ovo
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
BR112012001764A8 (pt) Método para prover um programa de treinamento incluindo pelo menos um primeiro exercício e um segundo exercício e sistema para prover a um indivíduo um programa de treinamento incluindo pelo menos um primeiro exercício e um segundo exercício
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
BR112015024780A2 (pt) metodo para determinar radiosensibilidade
BR112014019277A8 (pt) Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica
BR112013001410A2 (pt) aparelhos biossensores e métodos dos mesmos
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
BR112014009223A2 (pt) método para o diagnóstico da doença de niemann-pick
BR112014003877A2 (pt) biomarcadores de micro-rna e métodos de uso dos mesmos
BR112012028711A2 (pt) métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit
BR112014012306A2 (pt) soluções de colina estabilizadas e métodos para preparar as mesmas
BR112014021993B8 (pt) "métodos para detecção de uma variação de nucleotídeo em uma sequência de ácido nucleico alvo através de um ensaio de ptoce"
BR112014014307A2 (pt) métodos e kits para detecção in situ à temperatura ambiente de um ácido nucleico alvo em uma amostra biológica
BR112013024347A2 (pt) composição estabilizadora para polímeros contendo halogênio
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2669 03/03/2022 QUANTO AO RELATORIO DESCRITIVO.